ProteoCell is a wholly privately owned biotechnology company.

ProteoCell develops the bioprocess manufacturing platform for the production of recombinant protein biotherapeutics in collaboration with other biotechnology companies as they advance their molecule towards commercial market. ProteoCell focuses its energies on partnering with other small and emerging scale biotechnology companies. Today ProteoCell Biotechnologies stands as a pioneer in industrial bioprocess. Growth management is a key for our dynamic management team.

ProteoCell is open to different opportunities in private financing, including strategic partnerships and other capital sources. Investment proceeds are directed towards growth in the company's IP platform and cGMP capability development. For information on investment opportunities, please contact:

Imad Nasrallah
President & CEO